NEW YORK – GenomOncology on Thursday said it has signed a collaboration agreement with Pillar Biosciences to develop a comprehensive workflow that can deliver personalized cancer treatment recommendations.
The collaboration will combine Cleveland-based GenomOncology's clinical decision support platform with Pillar's research-use-only (RUO) next-generation sequencing (NGS) panels to support informed decision making by providers based on patients' individual genomic profiles.
Pillar, which is headquartered in Natick, Massachusetts, markets RUO NGS panels for a range of cancers, including solid tumors, myeloid malignancies, multi-cancer panels, and biomarker-specific panels.
"This collaboration enables us to provide more comprehensive, actionable insights for cancer care, empowering healthcare providers to make better, more informed decisions," Garreth Hippe, GenomOncology chief commercial officer, said in a statement.
Pillar joins several other firms that are making use of GenomOncology's capabilities to support precision medicine. In September 2024, Precipio partnered with GenomOncology to incorporate its clinical genomic reporting software into its test for myeloid neoplasms. The company also has partnerships with Congenica and Genomenon, and in 2021, the Cleveland-based University Hospitals Seidman Cancer Center adopted its technology to match cancer patients with clinical trials on the basis of molecular biomarkers.